To confirm these results, we performed immunohistochemistry (IHC) analysis of the tumor samples of A549‐WT and A549‐SUCLG2‐KO using anti‐Ki67, anti‐TTF1, and anti‐SUCLG2 antibodies. This evidence concerns the gene SUCLG2 and neoplasm.